Abstract:Introduction Clozapine has known utility for treatment of psychosis in patients with Lewy Body Dementia and Parkinson's disease. Clozapine's benefits, including improvement in psychotic symptoms and reduced risk of extrapyramidal symptoms, are counterbalanced by its potentially life-threatening side effects, including agranulocytosis, myocarditis, and seizures. The risk of adverse effects may be elevated in older adults, at least in part due to increased clozapine levels in the setting of reduced albumin and possible reduced activity of the CYP1A2 and 3A4 enzymes. In this report, we present a case of a patient who developed fever and laboratory evidence of inflammation shortly after initiation of clozapine during the COVID-19 pandemic. Methods The patient was a woman in her 70s with psychiatric history of treatment-refractory major depressive disorder with psychotic features, who was admitted to an inpatient psychiatry unit with severe depressive symptoms, paranoia, and somatic delusions. She also had visual hallucinations, tremulousness, and DaTscan abnormalities raising concern for Lewy Body Dementia or Parkinson's disease dementia as potential contributors to her psychiatric symptoms, though MMSE score was within normal limits. Her depressive and psychotic symptoms were inadequately managed by ECT and first-line antipsychotic medications (quetiapine, olanzapine), so she was cross-tapered to clozapine. About halfway through her second week of taking clozapine, she developed a fever. She had sore throat, rhinorrhea, and mild chest tightness but no chest pain. Labs were notable for normal WBC count, normal ANC, elevated CRP, normal high-sensitivity troponin, and negative SARS-CoV-2 PCR. Clozapine was continued given unremarkable cardiac markers, but over the following days, ESR, CRP, LDH, ferritin, procalcitonin, and IL-6 were elevated while infectious workup was unrevealing. She underwent multiple SARS-CoV-2 tests given that her inflammatory marker profile was similar to what had been seen in hospitalized patients with COVID-19, but all tests were negative. On day 14, HS-troponin increased though she had no flu-like symptoms, no chest pain, and no eosinophilia. Clozapine was initially continued, but the next day, there was a rapid increase in NT-proBNP. This altered the risk-benefit analysis of continuing clozapine, so it was stopped. Metoprolol was started due to possibility that prolonged tachycardia could explain some of the elevation in NT-proBNP. Echocardiogram showed unchanged, normal left ventricular ejection fraction. During this period, differential diagnosis per medicine consult team included unknown viral illness (more likely) versus clozapine-induced myocarditis (less likely). In the days following cessation of clozapine, HS-troponin normalized, NT-proBNP significantly decreased, and fever resolved. Results Given the severity and persistence of her psychiatric symptoms and uncertainty as to whether previous constellation of findings was viral or clozapine induced, approximately one week after its initial discontinuation, clozapine rechallenge was initiated with ongoing guidance from the internal medicine consult team. She had a couple of transient instances of slightly elevated NT-proBNP and HS-troponin measurements during re-titration, as well as elevations in ESR and CRP. Three weeks into repeat titration, she developed a fever, elevated procalcitonin, and mildly elevated NT-proBNP, but infectious workup was negative. Fever resolved and HS-troponin remained normal, so clozapine was continued and NT-proBNP had normalized by two days later. She was discharged shortly thereafter, and final EKG prior to discharge was normal. She continued clozapine for about two months after discharge before it was tapered off in the setting of unsteady gait and ultimately discontinued. Conclusions This case highlights the inflammatory response that can be seen in patients taking clozapine and how difficult it can be to distinguish from the laboratory abnormalities caused by COVID-19 or other viral illnesses. Of note, a previously proposed case definition for clozapine-related myocarditis included the absence of confirmed viral infection as part of the diagnostic criteria. Given difficulty of making definitive diagnosis of clozapine-induced myocarditis, it would be beneficial for a clear case definition to be widely disseminated and implemented. It is currently unknown whether older patients, particularly those with Parkinson-plus syndromes or recent viral illness, are more likely to develop inflammatory responses to clozapine. It is possible that older patients, particularly those with significant medical comorbidity, may benefit from a slower clozapine up-titration. Further research may help clinicians counsel older patients on the risks and benefits of a clozapine retrial following an episode of possible myocarditis.

Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

Clozapine metabolism and cardiotoxicity: A prospective longitudinal study

Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

High rates of myocarditis with clozapine in the Hunter region of Australia

Patterns of C-reactive protein trends during clozapine titration and the onset of clozapine-induced inflammation: a case series of weekly and daily C-reactive protein monitoring

Case series and Literature review – Clozapine Induced Transient Myocarditis. Clinical characteristics and outcomes

COVID-19 or Clozapine? A Case of Likely Clozapine-Induced Systemic Inflammatory Response Syndrome

Clozapine monitoring requirements: is it time for an update?

Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals

Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data

Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction

Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study

Toxic Rise of Clozapine Plasma Concentrations in Relation to Inflammation

Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations

Clozapine-related tachycardia: A conundrum to identify and treat

The effect of clozapine on immune-related biomarkers in schizophrenia patients

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT

Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia